Bristol Myers Squibb and Ipsen Pharma could soon find out whether the European Medicines Agency will back their requests to extend the indications of their respective cancer drugs as first-line treatments for advanced renal cell carcinoma (RCC) when used in combination with each other.
The combination of BMS’ Opdivo (nivolumab) and Ipsen Pharma’s Cabometyx (cabozantinib) is already approved in the US as first-line treatment for advanced RCC based on the results of the Phase III CheckMate -9ER trial